Trevi Therapeutics GAAP EPS of -$0.11 beats by $0.01 (TRVI:NASDAQ)

Other income, net: Other income, net was $0.8 million in the fourth quarter of 2024 compared to $1.1 million in the same period of 2023. The decrease was primarily due to lower cash equivalent and marketable securities balances and lower interest rate yields.